share_log
  • 要闻
  • 万基遗传扩大与illumina的合作，以增强癌症检测的基因组分析。

Myriad Genetics Expands Partnership With Illumina to Enhance Genomic Profiling for Cancer Detection

Myriad Genetics Expands Partnership With Illumina to Enhance Genomic Profiling for Cancer Detection

万基遗传扩大与illumina的合作，以增强癌症检测的基因组分析。
Quiver Quantitative ·  11/20 16:41

Myriad Genetics updates its agreement with Illumina, integrating GIS for broader cancer diagnostics using TruSight Oncology 500 v2.

Myriad Genetics更新了与Illumina的协议，使用TruSight Oncology 500 v2整合了地理信息系统，用于

Quiver AI Summary

Quiver AI 摘要

Myriad Genetics has announced an update to its agreement with Illumina, which will allow the inclusion of its Genomic Instability Score (GIS) for Homologous Recombination Deficiency (HRD) in all samples analyzed via Illumina's TruSight Oncology 500 v2 assay. This change broadens the availability of GIS results across various cancer types, enhancing Myriad's oncology product portfolio. The collaboration aims to combine Myriad's HRD technology with Illumina's expertise to create advanced genomic profiling tools and expand clinical research opportunities, particularly for HRD-based therapies. Myriad's MyChoice CDx test, which detects tumors with homologous recombination deficiencies, will be further supported by this strategic partnership, which has evolved since its initial announcement in January 2021.

Myriad Genetics宣布更新与Illumina的协议，这将允许在通过Illumina的TruSight Oncology 500 v2测定分析的所有样本中纳入其同源重组缺陷（HRD）的基因组不稳定性评分（GIS）。这一变化扩大了各种癌症类型GIS结果的可用性，增强了Myriad的肿瘤学产品组合。该合作旨在将Myriad的HRD技术与Illumina的专业知识相结合，以创建先进的基因组分析工具并扩大临床研究机会，特别是基于HRD的疗法。Myriad的MyChoice CDx测试用于检测具有同源重组缺陷的肿瘤，将得到自2021年1月首次宣布以来不断发展的战略合作伙伴关系的进一步支持。

Potential Positives

潜在的积极因素

  • Expansion of collaboration with Illumina allows for the inclusion of Myriad's Genomic Instability Score in all samples analyzed with the TruSight Oncology 500 v2 assay, enhancing diagnostic capabilities.
  • Broader availability of GIS results for various cancer types could strengthen Myriad's position in the oncology market and attract more healthcare providers to use their technology.
  • The integration of Myriad's HRD technology with Illumina's expertise may boost clinical research opportunities and drive development of companion diagnostics, potentially increasing revenue streams.
  • 扩大与Illumina的合作允许在使用TruSight Oncology 500 v2测定分析的所有样本中纳入Myriad的基因组不稳定性评分，从而增强诊断能力。
  • 更广泛地提供各种癌症类型的地理信息系统结果可以巩固Myriad在肿瘤学市场的地位，并吸引更多的医疗保健提供者使用他们的技术。
  • 将Myriad的人力资源开发技术与Illumina的专业知识相结合，可能会增加临床研究机会并推动伴随诊断的发展，从而有可能增加收入来源。

Potential Negatives

潜在的负面因素

  • The press release contains several forward-looking statements that are subject to known and unknown risks and uncertainties which could result in actual outcomes differing materially from expectations.
  • Myriad's reliance on the collaboration with Illumina for expanding its technology and product offerings could expose the company to risks related to partnership dependencies and potential changes in the collaboration's terms or effectiveness.
  • The announcement primarily highlights the technical aspects of the collaboration but does not provide clear insights into the commercial implications or expected financial benefits, leaving a gap in transparency regarding the partnership's potential impact on revenue and market position.
  • 新闻稿包含几项前瞻性陈述，这些陈述受已知和未知的风险和不确定性的影响，可能导致实际结果与预期存在重大差异。
  • Myriad依赖与Illumina的合作来扩大其技术和产品供应，这可能会使公司面临与合作伙伴关系以及合作条款或有效性潜在变化相关的风险。
  • 该公告主要强调了合作的技术方面，但并未就商业影响或预期的财务收益提供明确的见解，从而在伙伴关系对收入和市场地位的潜在影响方面留下了透明度差距。

FAQ

常见问题

What is the latest update from Myriad Genetics regarding Illumina?

Myriad Genetics 关于 Illumina 的最新更新是什么？

Myriad Genetics has updated its agreement with Illumina to include its Genomic Instability Score in all samples analyzed with Illumina's TruSight Oncology 500 v2.

Myriad Genetics更新了与Illumina的协议，将其基因组不稳定性评分纳入使用Illumina的TruSight Oncology 500 v2分析的所有样本中。

How will the partnership with Illumina affect cancer testing?

与Illumina的合作将如何影响癌症检测？

This partnership will broaden the range of cancer types that can receive Genomic Instability Score results and their homologous recombination deficiency status.

这种伙伴关系将扩大可以获得基因组不稳定性评分结果的癌症类型及其同源重组缺陷状态的范围。

What technologies are combined in Myriad's tests?

Myriad 的测试中结合了哪些技术？

Myriad's MyChoice CDx test combines tumor sequencing of BRCA1 and BRCA2 with proprietary technologies assessing loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions.

Myriad 的 MyChoice CDx 测试将 BRCA1 和 BRCA2 的肿瘤测序与评估杂合丢失、端粒等位基因失衡和大规模状态转变的专有技术相结合。

What is the significance of the Genomic Instability Score (GIS)?

基因组不稳定性分数（GIS）的意义是什么？

The GIS helps identify tumors deficient in homologous recombination, indicating higher susceptibility to certain cancer treatments like platinum drugs and PARP inhibitors.

地理信息系统有助于识别缺乏同源重组的肿瘤，表明对铂药物和PARP抑制剂等某些癌症治疗的敏感性更高。

How does this collaboration enhance Myriad's oncology product portfolio?

这种合作如何增强了Myriad的肿瘤学产品组合？

The inclusion of GIS in Myriad's Precise Tumor clinical reports will strengthen its oncology product offerings, enhancing comprehensive genomic profiling capabilities.

将GIS纳入Myriad的精确肿瘤临床报告将加强其肿瘤学产品供应，增强全面的基因组分析能力。

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

免责声明：这是由人工智能生成的 GlobeNewswire 发布的新闻稿摘要。用于总结此版本的模型可能会出错。在此处查看完整版本。


$MYGN Insider Trading Activity

$MYGN 内幕交易活动

$MYGN insiders have traded $MYGN stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.

在过去的6个月中，$MYGN内部人士在公开市场上交易了9次$MYGN股票。在这些交易中，0笔是购买，9笔是销售。

Here's a breakdown of recent trading of $MYGN stock by insiders over the last 6 months:

以下是内部人士在过去6个月中最近交易的MYGN股票的明细：

  • PAUL J DIAZ (President and CEO) has traded it 2 times. They made 0 purchases and 2 sales, selling 30,000 shares.
  • DALE MUZZEY (Chief Scientific Officer) sold 2,100 shares.
  • HEINRICH DREISMANN sold 10,000 shares.
  • COLLEEN F REITAN sold 46,012 shares.
  • MARGARET ANCONA (SVP, Chief of Staff) sold 11,538 shares.
  • RASHMI KUMAR sold 7,500 shares.
  • DANIEL K SPIEGELMAN has traded it 2 times. They made 0 purchases and 2 sales, selling 7,576 shares.
  • 保罗·迪亚兹（总裁兼首席执行官）已经进行了2次交易。他们进行了0次购买和2次销售，出售了30,000股股票。
  • 戴尔·穆齐（首席科学官）出售了2,100股股票。
  • 海因里希·德雷斯曼出售了10,000股股票。
  • COLLEEN F REITAN出售了46,012股股票。
  • 玛格丽特·安科纳（高级副总裁、办公厅主任）出售了11,538股股票。
  • 拉什米·库马尔出售了7,500股股票。
  • DANIEL k SPIEGELMAN 已经交易了 2 次。他们进行了0次购买和2次销售，出售了7,576股股票。

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

要追踪内幕交易，请查看Quiver Quantization的内幕交易仪表板。

$MYGN Hedge Fund Activity

$MYGN 对冲基金活动

We have seen 130 institutional investors add shares of $MYGN stock to their portfolio, and 106 decrease their positions in their most recent quarter.

我们已经看到130名机构投资者在其投资组合中增加了MYGN股票的股票，106家机构投资者在最近一个季度减少了头寸。

Here are some of the largest recent moves:

以下是近期一些最大的走势：

  • GLENVIEW CAPITAL MANAGEMENT, LLC removed 2,486,902 shares (-66.3%) from their portfolio in Q3 2024
  • CITADEL ADVISORS LLC removed 1,695,989 shares (-96.1%) from their portfolio in Q3 2024
  • CAMBER CAPITAL MANAGEMENT LP removed 1,550,000 shares (-28.2%) from their portfolio in Q3 2024
  • WELLINGTON MANAGEMENT GROUP LLP removed 1,545,842 shares (-18.7%) from their portfolio in Q3 2024
  • LOOMIS SAYLES & CO L P added 1,326,497 shares (+153.7%) to their portfolio in Q3 2024
  • MILLENNIUM MANAGEMENT LLC added 777,499 shares (+17.7%) to their portfolio in Q3 2024
  • MORGAN STANLEY removed 491,650 shares (-35.8%) from their portfolio in Q3 2024
  • 格伦维尤资本管理有限责任公司在2024年第三季度从其投资组合中删除了2,486,902股股票（-66.3％）
  • CITADEL ADVISORS LLC在2024年第三季度从其投资组合中删除了1,695,989股股票（-96.1％）
  • CAMBER CAPITAL Management LP 在 2024 年第三季度从其投资组合中删除了 1,550,000 股股票（-28.2%）
  • 惠灵顿管理集团有限责任公司在2024年第三季度从其投资组合中删除了1,545,842股股票（-18.7％）
  • LOOMIS SAYLES & CO L P 在 2024 年第三季度在其投资组合中增加了 1,326,497 股（+153.7%）
  • 千禧管理有限责任公司在2024年第三季度在其投资组合中增加了777,499股股票（+17.7％）
  • 摩根士丹利在2024年第三季度从其投资组合中删除了491,650股股票（-35.8％）

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

要追踪对冲基金的股票投资组合，请查看Quiver Quantization的机构持股仪表板。

Full Release

完整版本



SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) --

Myriad Genetics, Inc

. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies.


盐湖城，2024 年 11 月 20 日（环球新闻专线）—

无数遗传学公司

。基因测试和精准医疗领域的领导者纳斯达克股票代码：MYGN）宣布更新与DNA测序和基于阵列的技术领域的全球领导者Illumina Inc.（纳斯达克股票代码：ILMN）的协议。



Myriad's gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina's updated research assay, TruSight Oncology 500 v2 (TSO 500 v2). Previously, GIS to determine HRD was only available as a separate product. As a result, a broad array of cancer types will receive GIS results and their HRD status.


对于使用Illumina最新的研究测定TruSight Oncology 500 v2（TSO 500 v2）分析的所有样本，将报告用于确定同源重组缺陷（HRD）的黄金标准基因组不稳定性分数（GIS）。以前，用于确定人力资源开发的 GIS 只能作为单独的产品提供。因此，各种癌症类型将获得GIS结果及其HRD状态。



"We are pleased to expand our collaboration with Illumina and combine the two companies' technologies to create what we believe is the most advanced and complete gene panel to enable comprehensive genomic profiling," said Patrick Burke, PhD, EVP of Strategy and Innovation, Myriad Genetics.


Myriad Genetics战略与创新执行副总裁Patrick Burke博士表示：“我们很高兴扩大与Illumina的合作，并将两家公司的技术相结合，创建了我们认为最先进、最完整的基因组分析，以实现全面的基因组分析。”



Combining Myriad's HRD technology, which is used in MyChoice



CDx tumor-based test, with Illumina's expertise in comprehensive genomic profiling will enable Myriad to broaden clinical research opportunities and potentially drive CDx development for HRD-based therapies across multiple potential tumor types. Broad availability of data and the Myriad GIS platform may help drive disease-site indication expansion and potential companion diagnostic product development beyond ovarian cancer.


结合了 MyChoice 中使用的 Myriad 的人力资源开发技术



基于CDx肿瘤的测试，加上Illumina在全面基因组分析方面的专业知识，将使Myriad能够扩大临床研究机会，并有可能推动基于HRD的疗法针对多种潜在肿瘤类型的CDx开发。广泛的可用数据和Myriad GIS平台可能有助于推动疾病部位适应症的扩展和除卵巢癌之外的潜在伴随诊断产品的开发。



"Inclusion of GIS in all Myriad's

Precise Tumor




clinical reports will strengthen the company's oncology product portfolio," said Burke. "Precise Tumor is a pan-cancer solid tumor comprehensive genomic profiling test, leveraging Illumina's current TSO 500 technology."


“在所有 Myriad 中都包含 GIS

精准肿瘤




临床报告将加强该公司的肿瘤学产品组合，” 伯克说。“Precise Tumor是一项泛癌实体瘤综合基因组分析测试，利用了Illumina目前的TSO 500技术。”



Myriad announced the strategic partnership with Illumina in

January 2021

and has expanded its relationship both

geographically

and

technologically

since that time.


Myriad宣布与Illumina建立战略合作伙伴关系

2021 年 1 月

并扩大了双方的关系

地理位置

和

技术上

从那时起。




About Myriad's MyChoice CDx HRD Companion Diagnostic Test

Myriad's MyChoice CDx is the most comprehensive homologous recombination deficiency (HRD) test, enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The

MyChoice test

comprises tumor sequencing of the

BRCA1

and

BRCA2

genes and a composite of three proprietary technologies (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions).



关于 Myriad 的 MyChoice CDx HRD 配套诊断测试

Myriad的MyChoice CDx是最全面的同源重组缺陷（HRD）测试，它使医生能够识别已失去修复双链DNA断裂能力的肿瘤患者，从而增加对铂类药物或PARP抑制剂等DNA破坏药物的易感性。这个

MyChoice 测试

包括肿瘤测序

BRCA1

和

BRCA2

基因和三种专有技术的复合物（杂合性丧失、端粒等位基因失衡和大规模状态转换）。




About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit



.



关于《无数遗传学》

Myriad Genetics是一家领先的基因检测和精准医疗公司，致力于促进所有人的健康和福祉。Myriad 开发并提供基因检测，帮助评估发生疾病或疾病进展的风险，指导各医学专业的治疗决策，在这些专业领域，基因洞察可以显著改善患者护理并降低医疗成本。欲了解更多信息，请访问



.




Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company's Genomic Instability Score (GIS) will be reported for all samples analyzed with TSO 500 v2, a broader array of cancer types will receive GIS results and their HRD status, the company's agreement with Illumina will expand world-wide access to the company's technology and better position the company's GIS as a potential companion diagnostic across multiple potential tumor types, combining the company's HRD technology with Illumina's expertise in comprehensive genomic profiling will enable the company to broaden clinical research opportunities and potentially drive CDx development for HRD-based therapies across multiple potential tumor types, broad availability of data and the company's GIS platform may help drive disease-site indication expansion and potential companion diagnostic product development beyond ovarian cancer, and the inclusion of GIS in all Myriad's Precise Tumor clinical reports will strengthen the company's oncology product portfolio. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.



安全港声明

本新闻稿包含1995年《私人证券诉讼改革法》所指的 “前瞻性陈述”，包括将报告使用TSO 500 v2分析的所有样本的公司的基因组不稳定性分数（GIS），更广泛的癌症类型将获得GIS结果及其HRD状态，该公司与Illumina的协议将扩大全球获得公司技术的机会，并更好地将公司的GIS定位为多种潜在肿瘤的潜在辅助诊断工具类型，结合公司的人力资源开发部加上Illumina在全面基因组分析方面的专业知识的技术将使该公司能够扩大临床研究机会，并有可能推动基于HRD的疗法针对多种潜在肿瘤类型的CDx开发，数据的广泛可用性和公司的GIS平台可能有助于推动卵巢癌以外的疾病部位适应症扩展和潜在伴随诊断产品的开发，而在Myriad的所有精确肿瘤临床报告中纳入GIS将加强该公司的肿瘤产品组合。这些 “前瞻性陈述” 是管理层截至本文发布之日对未来事件的预期，受已知和未知的风险和不确定性的影响，这些风险和不确定性可能导致实际业绩、状况和事件与预期存在重大不利差异。这些因素包括公司向美国证券交易委员会提交的文件中描述的风险，包括该公司于2024年2月28日提交的10-k表年度报告，以及不时在公司10-Q表季度报告或8-k表最新报告中对这些风险因素的任何更新。除非法律要求，否则Myriad没有任何义务更新或修改任何前瞻性陈述，无论是由于新信息、未来事件还是其他原因。




Investor Contact

Matt Scalo
(801) 584-3532


IR@myriad.com




投资者联系方式

马特·斯卡洛
(801) 584-3532


IR@myriad.com





Media Contact

Glenn Farrell
(385) 318-3718


PR@myriad.com




媒体联系人

格伦·法雷尔
(385) 318-3718


PR@myriad.com




声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间